Cargando…

KRAS mutant colorectal cancer gene signatures identified angiotensin II receptor blockers as potential therapies

Colorectal cancer (CRC) is a life-threatening disease with high prevalence and mortality worldwide. The KRAS oncogene is mutated in approximately 40% of CRCs. While antibody based EGFR inhibitors (cetuximab and panitumumab) represent a major treatment strategy for advanced KRAS wild type (KRAS-WT) C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wen, Qing, Dunne, Philip D., O’Reilly, Paul G., Li, Gerald, Bjourson, Anthony J., McArt, Darragh G., Hamilton, Peter W., Zhang, Shu-Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5356876/ https://www.ncbi.nlm.nih.gov/pubmed/27965461 http://dx.doi.org/10.18632/oncotarget.13884

Ejemplares similares

Identification of Candidate Small-Molecule Therapeutics to Cancer by Gene-Signature Perturbation in Connectivity Mapping
por: McArt, Darragh G., et al.
Publicado: (2011)

Embracing an integromic approach to tissue biomarker research in cancer: Perspectives and lessons learned
por: Li, Gerald, et al.
Publicado: (2017)

RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer
por: Khawaja, Hajrah, et al.
Publicado: (2020)

Cancer-cell intrinsic gene expression signatures overcome intratumoural heterogeneity bias in colorectal cancer patient classification
por: Dunne, Philip D., et al.
Publicado: (2017)

QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
por: O’Reilly, Paul G., et al.
Publicado: (2016)

Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer
por: Dunne, Philip D., et al.
Publicado: (2016)

Particle swarm optimization artificial intelligence technique for gene signature discovery in transcriptomic cohorts
por: Murphy, Ross G., et al.
Publicado: (2022)

cudaMap: a GPU accelerated program for gene expression connectivity mapping
por: McArt, Darragh G, et al.
Publicado: (2013)

Connectivity Mapping for Candidate Therapeutics Identification Using Next Generation Sequencing RNA-Seq Data
por: McArt, Darragh G., et al.
Publicado: (2013)

Translation of tissue-based artificial intelligence into clinical practice: from discovery to adoption
por: Geaney, Alice, et al.
Publicado: (2023)

Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer
por: Hutchinson, Ryan A, et al.
Publicado: (2015)

Validation of Next Generation Sequencing Technologies in Comparison to Current Diagnostic Gold Standards for BRAF, EGFR and KRAS Mutational Analysis
por: McCourt, Clare M., et al.
Publicado: (2013)

Impact of Variable RNA-Sequencing Depth on Gene Expression Signatures and Target Compound Robustness: Case Study Examining Brain Tumor (Glioma) Disease Progression
por: Stupnikov, Alexey, et al.
Publicado: (2018)

Connectivity mapping using a combined gene signature from multiple colorectal cancer datasets identified candidate drugs including existing chemotherapies
por: Wen, Qing, et al.
Publicado: (2015)

KRAS mutant colorectal tumors: Past and present
por: Brand, Toni M., et al.
Publicado: (2012)

Transcriptional upregulation of c-MET is associated with invasion and tumor budding in colorectal cancer
por: Bradley, Conor A., et al.
Publicado: (2016)

Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation
por: Naccarelli, Gerald V, et al.
Publicado: (2009)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancer
por: Hashemzehi, Milad, et al.
Publicado: (2021)

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer
por: Dunne, Philip D., et al.
Publicado: (2018)

NUQA: Estimating Cancer Spatial and Temporal Heterogeneity and Evolution through Alignment-Free Methods
por: Roddy, Aideen C, et al.
Publicado: (2019)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Integrated multi-omics characterization of KRAS mutant colorectal cancer
por: Chong, Wei, et al.
Publicado: (2022)

Prospective patient stratification into robust cancer‐cell intrinsic subtypes from colorectal cancer biopsies
por: Alderdice, Matthew, et al.
Publicado: (2018)

Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy
por: Salama, Guy
Publicado: (2022)

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq
por: Al-Hussaniy, Hany A., et al.
Publicado: (2023)

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
por: Bibby, Becky A. S., et al.
Publicado: (2021)

IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer
por: Hutchinson, Ryan A, et al.
Publicado: (2017)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

Angiotensin receptor blocker add-on therapy in portal hypertension: To use angiotensin receptor blocker or not to use, that is the question
por: Lee, Hyun Woong
Publicado: (2014)

Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer
por: Knickelbein, Kyle, et al.
Publicado: (2014)

Bromelain effectively suppresses Kras-mutant colorectal cancer by stimulating ferroptosis
por: Park, Sujeong, et al.
Publicado: (2018)

Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer
por: Zhong, Longhui, et al.
Publicado: (2020)

Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer
por: Ruan, Hang, et al.
Publicado: (2022)

Angiotensin receptor blockers and COVID-19
por: Saavedra, Juan M.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0eg504m7jee7h9jc33m4mjdgj1